About the dataset

Primary description: Alzheimer’s biomarkers and progression

The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a public–private partnership coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. Since its launch in 2003 under the leadership of Principal Investigator Michael W. Weiner, MD, 63 sites across the United States and Canada have contributed to the ongoing effort to identify, track, and understand Alzheimer’s disease (AD) and its early stages. The study collects longitudinal multimodal data, including structural and functional MRI, positron emission tomography (PET) with FDG, PiB, and AV-45 tracers, biological samples (blood, urine, and cerebrospinal fluid in a subset), and comprehensive clinical and neuropsychological assessments from over 1,000 participants with AD, mild cognitive impairment (MCI), or age-matched controls.

Study Alzheimer’s Disease Neuroimaging Initiative
Study Website ADNI
Data Descriptor Paper https://pmc.ncbi.nlm.nih.gov/articles/PMC2809036/
DUA https://adni.loni.usc.edu/wp-content/themes/adni_2023/documents/ADNI_Data_Use_Agreement.pdf
Country/Region USA/Canada
Disease Tags alzheimers
Age (mean ± SD) 73.1 ± 7.3
% Female 47.7
Age Range 55-90
N Subjects 2517
N MR Sessions 10913
CUBIC Project /cbica/projects/ADNI
DLMUSE (version ???)
(10858/10913 complete)
/cbica/projects/ADNI/Pipelines/ADNI_DLMUSE_2025/Results/DLMUSE_Volumes.csv
DLWMLS (version ???)
(6075/10913 complete)
/cbica/projects/ADNI/Pipelines/ADNI_DLWMLS_2025/Results/ADNI_DLWMLS_DLMUSE_Segmented_Volumes.csv


Funding
ADNI (National Institutes of Health Grant U01 AG024904, U01 AG072177) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012) are funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. MESA is supported by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute, and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from the National Center for Advancing Translational Sciences (NCATS). Brain MRI is supported by grant R01 HL127659 from the National Heart, Lung, and Blood Institute with additional support from the National Institute on Aging and grant R01 AG080821.